K. Thomas Bailey Net Worth

The estimated Net Worth of K Thomas Bailey is at least $5.09 Milione dollars as of 6 May 2024. Mr. Bailey owns over 182,702 units of Nanostring Technologies Inc stock worth over $32,028 and over the last 7 years he sold NSTG stock worth over $2,946,016. In addition, he makes $2,108,690 as Chief Financial Officer at Nanostring Technologies Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Bailey NSTG stock SEC Form 4 insiders trading

K has made over 27 trades of the Nanostring Technologies Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 182,702 units of NSTG stock worth $19,239 on 6 May 2024.

The largest trade he's ever made was exercising 182,702 units of Nanostring Technologies Inc stock on 6 May 2024 worth over $19,239. On average, K trades about 16,230 units every 53 days since 2018. As of 6 May 2024 he still owns at least 304,163 units of Nanostring Technologies Inc stock.

You can see the complete history of Mr. Bailey stock trades at the bottom of the page.

K. Thomas Bailey biography

K. Thomas Bailey serves as Chief Financial Officer of the Company. Prior to joining our company, Mr. Bailey was Chief Financial Officer at AgaMatrix Holdings LLC, a developer, manufacturer and marketer of medical technologies for diabetes care, from March 2014 to January 2018. Prior to joining AgaMatrix, Mr. Bailey served as Chief Executive Officer of Angiotech Pharmaceuticals, a developer, manufacturer and marketer of local drug, drug delivery and medical device technologies, from October 2011 to October 2013, and served as Angiotech’s Chief Financial Officer from December 2005 to October 2011. During his time as CFO of Angiotech, Mr. Bailey directed a restructuring of Angiotech’s debt obligations pursuant to the Canadian Creditors Arrangement Act in 2011, with recognition of the restructuring pursuant to Chapter 15 under U.S. law. Mr. Bailey also serves as a Director of AgaMatrix Holdings, SCP Interventional Radiology LLC and The Homestretch Foundation, and previously served as a Director of Angiotech Pharmaceuticals, LifeCare Management Services and OncoGenex Inc. Previously, Mr. Bailey served as a Director in the health care investment banking group at Credit Suisse First Boston and Donaldson, Lufkin & Jenrette. Mr. Bailey received an A.B. in economics from Harvard University in 1990 and an M.B.A. from Harvard Business School in 1995.

What is the salary of K Bailey?

As the Chief Financial Officer of Nanostring Technologies Inc, the total compensation of K Bailey at Nanostring Technologies Inc is $2,108,690. There are 1 executives at Nanostring Technologies Inc getting paid more, with R. Bradley Gray having the highest compensation of $7,288,840.

How old is K Bailey?

K Bailey is 51, he's been the Chief Financial Officer of Nanostring Technologies Inc since 2018. There are 16 older and 2 younger executives at Nanostring Technologies Inc. The oldest executive at Nanostring Technologies Inc is William Young, 75, who is the Independent Chairman of the Board.

What's K Bailey's mailing address?

K's mailing address filed with the SEC is 530 Fairview Ave N, Seattle, WA 98109, USA.

Insiders trading at Nanostring Technologies Inc

Over the last 11 years, insiders at Nanostring Technologies Inc have traded over $114,083,977 worth of Nanostring Technologies Inc stock and bought 981,722 units worth $9,126,410 . The most active insiders traders include Charles P Jr Waite, Lifesciences Ii, L.P.Clarus... e Nicholas Galakatos. On average, Nanostring Technologies Inc executives and independent directors trade stock every 16 days with the average trade being worth of $4,371. The most recent stock trade was executed by Joseph M Beechem on 6 May 2024, trading 147,853 units of NSTG stock currently worth $15,569.

What does Nanostring Technologies Inc do?

nanostring technologies (nasdaq: nstg) is a publicly held provider of life science tools for translational research and molecular diagnostics. the company's technology enables a wide variety of basic research, translational medicine and in vitro diagnostics applications. nanostring technologies provides life science tools for translational research and molecular diagnostic products. the company's ncounter® analysis system, which has been employed in basic and translational research since it was first introduced in 2008 and cited in more than 300 peer-reviewed publications, has also now been applied to diagnostic use as the ncounter dx analysis system. the company's technology offers a cost-effective way to easily profile the expression of hundreds of genes, mirnas, or copy number variations, simultaneously with high sensitivity and precision. the company's technology enables a wide variety of basic research and translational medicine applications, including biomarker discovery and vali

Complete history of Mr. Bailey stock trades at Nanostring Technologies Inc

Nanostring Technologies Inc executives and stock owners

Nanostring Technologies Inc executives and other stock owners filed with the SEC include:

• R. Bradley Gray,
  President, Chief Executive Officer, Director
• K. Thomas Bailey,
  Chief Financial Officer
• Joseph Beechem,
  Senior Vice President - Research and Development
• John Brown,
  Senior Vice President - Sales and Marketing
• David Ghesquiere,
  Senior Vice President - Corporate and Business Development
• R. Bradley Gray,
  CEO, Pres & Director
• K. Thomas Bailey M.B.A.,
  Chief Financial Officer
• Dr. Joseph M. Beechem,
  Chief Scientific Officer and Sr. VP of R&D
• J. Chad Brown,
  Sr. VP of Sales & Marketing
• David W. Ghesquiere,
  Sr. VP of Corp. & Bus. Devel.
• William Young,
  Independent Chairman of the Board
• Gregory Norden,
  Independent Director
• Don Kania,
  Independent Director
• Charles Waite,
  Independent Director
• Elisha Finney,
  Independent Director
• Kirk Malloy,
  Independent Director
• Robert Hershberg,
  Independent Director
• Elizabeth Schneider Ph.D.,
  Sr. Global Marketing Mang.
• Dr. Philippa Webster Ph.D.,
  Sr. Principal Scientist
• Dr. Mary Tedd Allen,
  Sr. VP of Strategic Initiatives
• Kathryn Surace-Smith,
  Sr. VP of HR & Legal Affairs and Corp. Sec.
• Douglas S. Farrell,
  VP of Investor Relations & Corp. Communications
• Mark A. Winham,
  Sr. VP of Operations
• Teresa M. Foy,
  Director
• Nicholas Galakatos,
  Director
• Lifesciences Ii, L.P.Clarus...,
  
• Wayne Burns,
  SVP, Operations & Admin
• James A Johnson,
  Chief Financial Officer
• J. Chad Brown,
  SVP, Sales & Marketing
• Mary Tedd Allen,
  SVP, Operations
• Lifesciences Ii, L.P.Clarus...,
  
• Barney Saunders,
  SVP & GM, Life Sciences
• Venture Partners Vi Lpovp V...,
  
• Fisher Jurvetson Fund Vii, ...,
  
• Finny Kuruvilla,
  Director
• Tina Susan Nova,
  Director
• Bruce J. Seeley,
  SVP & GM, Diagnostics
• J Wayne Cowens,
  Chief Medical Officer
• Jennifer Scott Fonstad,
  Director
• Bradford Crutchfield,
  Director
• Janet George,
  Director
• Dana E. Rollison,
  Director
• John D. Gerace,
  Chief Commercial Officer
• Jonathan Todd Garland,
  Chief Commercial Officer